Alimera Sciences Reports Second Quarter 2023 Results
10. August 2023 07:30 ET
|
Alimera Sciences, Inc.
Alimera Acquired U.S. Commercial Rights to YUTIQ®Landmark NEW DAY Study Completed Enrollment with over 300 PatientsConsolidated Net Revenue of $17.5 Million Up 20% vs. Second Quarter of 2022Global End...
Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update
02. August 2023 11:43 ET
|
Alimera Sciences, Inc.
ATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Completes Recruitment for its Landmark NEW DAY Study
24. Mai 2023 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, May 24, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Acquires U.S. Commercial Rights to YUTIQ®
18. Mai 2023 07:00 ET
|
Alimera Sciences, Inc.
Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023 Alimera projects at least $100 million of consolidated net revenue and over $20 million of Adjusted EBITDA* in 2024...
Alimera Sciences to Host Rescheduled Corporate Update Call on Thursday, May 18, 2023, at 8:30am ET
17. Mai 2023 16:05 ET
|
Alimera Sciences, Inc.
ATLANTA, May 17, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Reports First Quarter 2023 Results
15. Mai 2023 07:50 ET
|
Alimera Sciences, Inc.
Consolidated Net Revenue of $13.5 Million Up 14% vs. First Quarter of 2022Global End User Demand Up 14% vs. First Quarter of 2022 Financial Results and Corporate Update Conference Call Cancelled ...
Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update
08. Mai 2023 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, May 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Data to be Featured in Scientific Programming at Upcoming Annual Congress
20. April 2023 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, April 20, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in the Nordic Countries
03. April 2023 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, April 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Announces 2022 Financial Results and Business Update
31. März 2023 08:00 ET
|
Alimera Sciences, Inc.
• 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021 • Global End User Demand Increased 22% over 2021 to 9,266 Units • Strengthened Balance Sheet, Repurchased Stock and Extended Term...